Coronavirus Clash: Global Pharma Scrambles In Locking Down World
Managing Change In Unprecedented Crisis
Executive Summary
A former pharma executive shares views with Scrip about the coronavirus in China, the challenges facing corporations and individuals in a rapidly changing world and coming threats that could potentially cause even more damage than the pandemic.
You may also be interested in...
From Biogen To Bayer: Coronavirus A Stress Test For Pharma
When a global pandemic hits and local rules over personal movement are highly fluid and constantly updated, two pharma firms with a global footprint have faced unprecedented tests.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.